Communiqués Genexine, Inc.

Actions

Cours en clôture Korea S.E. 03/09/2026			Varia. 5j.	Varia. 1 janv.
3 260,00 ^KRW	+15,81%		+18,33%	-30,42%

28/04	Genexine Inc démontre l'efficacité de GX-BP1, son dégradeur de SOX2 'first-in-class', en modèles précliniques	CI
16/03	Egret Therapeutics, Inc et Genexine, Inc signent un protocole d'accord pour le transfert d'actifs de GX-P1 (EGT-101)	CI

29/05/23	Genexine abstract on GX-188E and GX-I7 triple combination therapy in HNSCC is released at 2023 ASCO Annual Meeting	AQ
23/01/23	Genexine Receives Fast Track Designation from Korean Health Authority (MFDS) for its promising DNA vaccine for advanced cervical cancer	AQ
25/08/22	Genexine selected for Late-Breaking Oral Presentation of Phase 2 Study of GX-188E in Combination with KEYTRUDA (pembrolizumab) in Cervical Cancer at European Society for Medical Oncology (ESMO) Congr	AQ
21/08/18	Genexine : Ichor Medical Systems Announces Utilization of Its Investigational TriGrid Delivery System in a Clinical Trial Evaluating GX-188E Vaccine Combined with a Checkpoint Inhibitor for Treatment of Cervical Cancer	BU
19/06/17	Genexine : Receives Approval to Initiate Phase Ib/II Trial of GX-188E, HPV Therapeutic DNA Vaccine, in Combination With KEYTRUDA® (pembrolizumab), for the Treatment of HPV-Induced Cervical Cancer	BU
28/12/16	Genexine : to Present at the 35th J.P. Morgan Healthcare Conference	BU
16/11/16	Genexine : Granted FDA Orphan Drug Designation for GX-H9 in Growth Hormone Deficiency	BU
16/11/16	Genexine : Enters into Clinical Research Collaboration with MSD	BU